Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-10-12
2004-07-27
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06767893
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to therapeutic uses of bactericidal/permeability-increasing (BPI) protein products for the treatment of adverse physiological effects associated with intestinal ischemia/reperfusion.
Reperfusion of ischemic intestines is associated with profound cardiovascular and respiratory dysfunction that may lead to shock and death. A variety of mediators are believed to be released from the ischemic tissue that could lead to cardiorespiratory collapse, including oxygen free radicals, protanoids, and platelet activating factor.
During ischemia, breakdown of the intestinal mucosal permeability barrier may result in translocation of endotoxin and/or bacteria from the intestinal lumen. Endotoxin has been detected in the portal vein after intestinal ischemia/reperfusion. However, a role for translocated bacteria or endotoxin in intestinal ischemia/reperfusion injury has not been clearly defined.
Bactericidal/permeability-increasing protein (BPI) is a protein isolated from the granules of mammalian PMNs, which are blood cells essential in the defense against invading microorganisms. Human BPI protein has been isolated from polymorphonuclear neutrophils by acid extraction combined with either ion exchange chromatography [Elsbach,
J. Biol. Chem.,
254:11000 (1979)] or
E. coli
affinity chromatography [Weiss, et al.,
Blood,
69:652 (1987)] referred to herein as natural BPI and has potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein, as well as the DNA encoding the protein, have been elucidated in
FIG. 1
of Gray et al.,
J. Biol. Chem.,
264:9505 (1989), incorporated herein by reference.
The bactericidal effect of BPI has been shown to be highly specific to sensitive gram-negative species, while non-toxic for other microorganisms and for eukaryotic cells. The precise mechanism by which BPI kills bacteria is as yet unknown, but it is known that BPI must first attach to the surface of susceptible gram-negative bacteria. This initial binding of BPI to the bacteria involves electrostatic interactions between the basic BPI protein and the negatively charged sites on lipopolysaccharides (LPS). LPS has been referred to as “endotoxin” because of the potent inflammatory response that it stimulates. LPS induces the release of mediators by host inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to Lipid A, the most toxic and most biologically active component of LPS.
In susceptible bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer membrane, and ultimately causing cell death by an as yet unknown mechanism. BPI is also capable of neutralizing the endotoxic properties of LPS to which it binds. Because of its gram-negative bactericidal properties and its ability to neutralize LPS, BPI can be utilized for the treatment of mammals suffering from diseases caused by gram-negative bacteria, such as bacteremia or sepsis. Bahrami et al.,
Int'l Endotoxin Soc. Meeting
, Vienna, Austria (August 1992), disclose the use of a BPI protein for the treatment of hemorrhagic shock.
A proteolytic fragment corresponding to the N-terminal portion of human BPI holoprotein possesses the antibacterial efficacy of the naturally-derived 55 kD human holoprotein. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI protein displays only slightly detectable anti-bacterial activity. Ooi, et al.,
J. Exp. Med.,
174:649 (1991). A BPI N-terminal fragment, comprising approximately the first 199 amino acid residues of the human BPI holoprotein and referred to as “rBPI
23
”, has been produced by recombinant means as a 23 kD protein. Gazzano-Santoro et al.,
Infect. Immun.
60:4754-4761 (1992).
SUMMARY OF THE INVENTION
The present invention provides novel methods for the treatment of adverse physiological effects associated with intestinal ischemia/reperfusion comprising administering BPI protein products to a subject suffering from the effects of intestinal ischemia/reperfusion. Specifically, the invention provides methods of treating the adverse physiological effects, including cardiac and hemodynamic effects, of intestinal ischemia/reperfusion resulting from a variety of causes. Such causes include mesenteric artery ischemia which is secondary to occlusions resulting from atherosclerosis, embolisms or arterial spasms; ischemia resulting from vessel occlusions in other segments of the bowel; ischemic colitis and intestinal torsion such as occurs in infants and particularly in animals. In particular, the invention provides methods for treating the adverse cardiac and other effects of intestinal ischemia and reperfusion associated with myocardial infarction.
The invention thus provides methods for treatment of sepsis-like conditions associated with intestinal ischemia/reperfusion comprising administering to a subject an amount of a BPI protein product effective to alleviate adverse physiological effects resulting from the presence of bacteria, bacterial particulates and endotoxin present in the body and in circulation in the blood.
REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5153178 (1992-10-01), Maroko
patent: 5171739 (1992-12-01), Scott
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5420019 (1995-05-01), Theofan et al.
patent: WO 89/12644 (1989-12-01), None
patent: WO 92/03535 (1992-03-01), None
patent: WO 92/09261 (1992-06-01), None
patent: WO 93/06228 (1993-04-01), None
patent: WO 93/23434 (1993-11-01), None
patent: WO 93/23540 (1993-11-01), None
Stedman's Medical Dictionary Search [online]. PDR® Electronic Library by Medical Economics Company, Inc. at Montvale, NJ 07645. [retrieved on Feb. 20, 2002]. Retrieved from Internet:<URL:http://www.pdrel.com/pdr/static.htm?path=controlled/searchstedman>.*
Grace PA. Ischaemia-reperfusion injury. Br J Surg. May 1994;81(5):637-47.*
Horton et al. Oxygen radicals, lipid peroxidation, and permeability changes after intestinal ischemia and reperfusion. J Appl Physiol. Apr. 1993;74(4):1515-20.*
Bone R C. Why sepsis trials fail. JAMA, (Aug. 21, 1996) 276 (7) 565-6.*
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (Mar. 16, 1990) 247 (4948) 1306-10.*
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*
Ammons, et al., An N-Terminal Fragment Of Bactericidal/Permeability Increasing Protein (rBPI21) Reduces Cardiorespiratory Dysfunction Resulting From Intestinal Ischemia/Reperfusion,Annual Meeting of Professional Scientific Research Scientists, Experimental Biology 94™, Anaheim, California, Abstracts 1-3391, Part I, Ischemic Injury, 753 (Apr. 24-28, 1994).
Bahrami, et al., “Endotoxemia In Rats Subjected To The Haemorrhage: Effects Of Bactericidal/Permeability Increasing Protein (BPI)”,Abstract Presented At Vienna International Endotoxin Society Meeting(Aug., 1992).
Bahrami, et al., “Bactericidal/Permeability-Increasing Protein (BPI) Reduces Lipopolysaccride (LPS)-Induced Cytokine Formation And Mortality In Rats,”Circulatory Shock, Supplement 1, Abstract 12.25P, Vienna, Austria (May 9-13, 1993).
Boermeester, et al., “Peri-operative prophylaxis with bactericidal/permeability-increasing protein (rBPI23) prevents early postoperative derangements following partial hepatectomy,”Intensive Care Medicine, vol. 20, Supplement 1, Abstract 478 (Mar., 1994).
Elsbach, et al., “Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A2from Rabbit
Ammons William Steve
Mészäros Károly M.
Marshall & Gerstein & Borun LLP
Romeo David S.
Xoma Corporation
LandOfFree
Method of treating conditions associated with intestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating conditions associated with intestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating conditions associated with intestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3186454